Chenglin Zhu

Ms. Chenglin Zhu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
QXQing Xiong
Qing Xiong
XHXinzi He
Xinzi He
Elisa ScalcoElisa Scalco
Elisa Scalco
SPSiria Pasini
Siria Pasini
CZChenglin Zhu
Chenglin Zhu
Martin R PrinceMartin R Prince
Martin R Prince
Key Points: TraceOrg is a web-based tool that automatically labels kidney, liver, and cysts, reporting volumes and Mayo Imaging Classification. External validation showed high performance and good generalizability on Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Polycystic Kidney Disease-Research Resource Consortium, and other external datasets. Training on multiple pulse sequences enables TraceOrg to process images from a wide variety of protocols. Background: Kidney, liver, and cyst volumes are important for diagnosis, classification, and management of autosomal dominant polycystic kidney disease (ADPKD) but challenging to measure accurately and reproducibly. Here, we develop a web-based deep learning platform to automatically and robustly measure kidneys, liver, and cyst volumes in ADPKD. Methods: Magnetic resonance imaging (MRI) and computed tomography scans from patients with ADPKD ( n =611) and participants without ADPKD ( n =109) were used to train a 3D hybrid model combining U-Net and transformer elements for segmenting kidneys, liver, and cysts. The model is implemented as a web-based calculator at www.traceorg.com, providing segmentation labels, volumes, and Mayo Clinic Image Classification. Automatic browser anonymization of digital imaging and communications in medicine images ensures privacy. Internal validation was conducted on 70 MRIs for kidney and liver segmentations and 46 MRIs for cyst segmentations, and performance was compared with five open access segmentation models (TotalSegmentator, MRAnnotator, Kim, Woznicki, and Gregory–Kline). External validation was performed on one single-center dataset ( n =58), one multicenter dataset ( n =73), Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease 2 (CRISP, n =30), and Polycystic Kidney Disease-Research Resource Consortium (PKD-RRC, n =115) MRIs with T2-weighted and T1-weighted images. Results: After training on 720 participants (mean age=48±15, eGFR=74±32 ml/min per 1.73 m 2 and height-adjusted total kidney volume=826±772 ml/m), TraceOrg internal validation performance achieved high mean Dice scores of 0.97 (kidneys), 0.97 (liver), 0.93 (kidney cysts), and 0.82 (liver cysts) outperforming existing models for ADPKD. External validation showed strong performance with Dice scores of 0.92–0.94 (kidney), 0.87–0.96 (liver), 0.85 (kidney cysts), and 0.76–0.90 (liver cysts) for the single-center dataset and 0.95 (kidney) and 0.81 (kidney cysts) for the multicenter dataset. Compared with CRISP volumes measured by stereology, the mean absolute percent difference was 5.3% (kidneys, n =30), 11% (kidney cysts, n =30), and 5.5% (liver, n =22). Compared with PKD-RRC ( n =115), the mean absolute percent difference in total kidney volume was 4.9%. Conclusions: TraceOrg, a publicly available web-based tool, automatically measured kidney, liver, and cyst volumes from abdominal MRI in ADPKD with high accuracy compared with manual segmentations. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2026_02_03_ASN0000000904.mp3

1 April 2024 in Kidney360
Verified
Journal Article
Open access
HDHreedi Dev
Hreedi Dev
CZChenglin Zhu
Chenglin Zhu
IBIrina Barash
Irina Barash
JBJon D. Blumenfeld
Jon D. Blumenfeld
XHXinzi He
Xinzi He
Martin R PrinceMartin R Prince
Martin R Prince
Key Points: Water therapy in autosomal dominant polycystic kidney disease (ADPKD) reduces urine osmolality and serum copeptin level, a marker of vasopressin activity. Water therapy reduces the ADPKD kidney growth rate indicating it is slowing disease progression. Patients with ADPKD are less likely to report pain on water therapy. Background: In animal models of autosomal dominant polycystic kidney disease (ADPKD), high water intake (HWI) decreases vasopressin secretion and slows disease progression, but the efficacy of HWI in human ADPKD is uncertain. Methods: This exploratory, prospective, cross-over study of patients with ADPKD (N=7) evaluated the hypothesis that HWI slows the rate of increase in height-adjusted total kidney volume (ht-TKV; a biomarker for ADPKD progression) and reduces pain. Patients at high risk of ADPKD progression (i.e., Mayo Imaging Classifications 1C/1D) were evaluated during 6 months of usual water intake (UWI), followed by 12 months of HWI calculated to reduce urine osmolality (Uosm) to <285 mOsm/kg. Measurements of Uosm, serum copeptin (secreted in equimolar amounts with vasopressin), magnetic resonance imaging measurements of ht-TKV, and pain survey responses were compared between HWI and UWI. Results: During HWI, mean 24-hour Uosm decreased compared with UWI (428 [398–432] mOsm/kg versus 209 [190–223] mOsm/kg; P = 0.01), indicating adherence to the protocol. Decreases during HWI also occurred in levels of serum copeptin (5.8±2.0 to 4.2±1.6 pmol/L; P = 0.03), annualized rate of increase in ht-TKV (6.8% [5.9–8.5] to 4.4% [3.0–5.0]; P < 0.02), and pain occurrence and pain interference during sleep (P < 0.01). HWI was well tolerated. Conclusions: HWI in patients at risk of rapid progression of ADPKD slowed the rate of ht-TKV growth and reduced pain. This suggests that suppressing vasopressin levels by HWI provides an effective nonpharmacologic treatment of ADPKD.

Verified
Journal Article
Open access
PDF file
Vahid BazojooVahid Bazojoo
Vahid Bazojoo
VDVahid Davoudi
Vahid Davoudi
JBJon Blumenfeld
Jon Blumenfeld
CZChenglin Zhu
Chenglin Zhu
LMLine Malha
Line Malha
Martin R PrinceMartin R Prince
Martin R Prince
Background/Objectives: Polycystic liver disease (PLD) is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). PLD is more prevalent in women, and women have larger liver cysts, possibly due to estrogen-related mechanisms. Maternal estrogen levels normally increase during pregnancy. Thus, we investigated the pregnancy-associated increase in liver volume, liver cyst volume, total kidney volume (TKV), and kidney cyst growth rates in ADPKD patients. Methods: Kidney, liver, and cyst volumes were measured in 16 ADPKD patients by magnetic resonance imaging (MRI) at multiple timepoints before and after pregnancy. The log-transformed TKV, liver volume, and cyst volume growth rates during a period with pregnancy were compared to a period without pregnancy. Results: In ADPKD patients, a higher annualized liver cyst growth rate was observed during a period with pregnancy compared to a period without pregnancy (34 ± 16%/yr vs. 23 ± 17%/yr; p-value = 0.005). Liver volume growth was also higher during a period with pregnancy, 6 [2, 7]%/yr vs. 0.3 [−0.4, 2]%/yr (p-value = 0.04). In addition, the mean kidney cyst growth rate was higher (12 ± 11%/yr vs. 4 ± 9%/yr; p-value = 0.05), and there was a trend toward a pregnancy-associated increase in the TKV growth rate (6 [4, 8]%/yr vs. 3 [0.8, 5]%/yr, (p-value = 0.14) during a period with pregnancy. Conclusions: In patients with ADPKD, the liver volume and cyst volume growth rates increased during pregnancy. This supports the hypothesis that the estrogen-mediated stimulation of liver cyst growth may contribute to the severe polycystic liver disease that is more prevalent in women than men with ADPKD. Further studies with larger populations are needed to explore the mechanisms and long-term implications of these findings.

21 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HDHreedi Dev
Hreedi Dev
ZHZhongxiu Hu
Zhongxiu Hu
JBJon Blumenfeld
Jon Blumenfeld
Arman SharbatdaranArman Sharbatdaran
Arman Sharbatdaran
YKYelynn Kim
Yelynn Kim
Martin R PrinceMartin R Prince
Martin R Prince
Background/Objectives: Although tolvaptan efficacy in ADPKD has been demonstrated in randomized clinical trials, there is no definitive method for assessing its efficacy in the individual patient in the clinical setting. In this exploratory feasibility study, we report a method to quantify the change in total kidney volume (TKV) growth rate to retrospectively evaluate tolvaptan efficacy for individual patients. Treatment-related changes in estimated glomerular filtration rate (eGFR) are also assessed. Methods: MRI scans covering at least 1 year prior to and during treatment with tolvaptan were performed, with deep learning facilitated kidney segmentation and fitting multiple imaging timepoints to exponential growth in 32 ADPKD patients. Clustering analysis differentiated tolvaptan treatment “responders” and “non-responders” based upon the magnitude of change in TKV growth rate. Differences in rate of eGFR decline, urine osmolality, and other parameters were compared between responders and non-responders. Results: Eighteen (56%) tolvaptan responders (mean age 42 ± 8 years) were identified by k-means clustering, with an absolute reduction in annual TKV growth rate of >2% (mean = −5.1% ± 2.5% per year). Thirteen (44%) non-responders were identified, with <1% absolute reduction in annual TKV growth rate (mean = +2.4% ± 2.7% per year) during tolvaptan treatment. Compared to non-responders, tolvaptan responders had significantly higher mean TKV growth rates prior to tolvaptan treatment (7.1% ± 3.6% per year vs. 3.7% ± 2.4% per year; p = 0.003) and higher median pretreatment spot urine osmolality (Uosm, 393 mOsm/kg vs. 194 mOsm/kg, p = 0.03), confirmed by multivariate analysis. Mean annual rate of eGFR decline was less in responders than in non-responders (−0.25 ± 0.04, CI: [−0.27, −0.23] mL/min/1.73 m2 per year vs. −0.40 ± 0.06, CI: [−0.43, −0.37] mL/min/1.73 m2 per year, p = 0.036). Conclusions: In this feasibility study designed to assess predictors of tolvaptan treatment efficacy in individual patients with ADPKD, we found that high pretreatment levels of annual TKV growth rate and higher pretreatment spot urine osmolality were associated with a responder phenotype.

11 July 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
USUsama Sattar
Usama Sattar
XYXiaorui Yin
Xiaorui Yin
XLXianfu Luo
Xianfu Luo
CZChenglin Zhu
Chenglin Zhu
ZHZhongxiu Hu
Zhongxiu Hu
MPMartin R. Prince
Martin R. Prince
BACKGROUND AND PURPOSE: Autosomal dominant polycystic kidney disease (ADPKD) patients develop cysts in the kidneys, liver, spleen, pancreas, prostate and arachnoid spaces. In addition, spinal meningeal diverticula have been reported. To determine whether spinal meningeal diverticula are associated with ADPKD, we compare their prevalence in ADPKD subjects to a control cohort without ADPKD. MATERIALS AND METHODS: ADPKD subjects and age-and gender-matched controls without ADPKD undergoing abdominal MRI from mid-thorax to the pelvis from 2003 to 2023 were retrospectively evaluated for spinal meningeal diverticula by 4 blinded observers. Prevalence of spinal meningeal diverticula in ADPKD was compared to control subjects, using t-test and correlated with clinical and laboratory data, and magnetic resonance imaging (MRI) features, including cyst volumes and cyst counts. RESULTS: Identification of spinal meningeal diverticula in ADPKD (n=285, median age, 47 [37,56]; 54% female) and control (n=285, median age, 47 [37,57]; 54% female) subjects had high inter-observer agreement (Pairwise Cohen kappa=0.74). Spinal meningeal diverticula were observed in 145 of 285 (51%) ADPKD subjects compared with 66 of 285 (23%) control subjects without ADPKD (p<0.001). Spinal meningeal diverticula in ADPKD were more prevalent in women (98 of 153 [64%]) than men (47 of 132 [36%], p<0.001). The mean number of spinal meningeal diverticula per affected ADPKD subject was 3.6 + 2.9 compared to 2.4 + 1.9 in controls with cysts (p<0.001). The median volume/interquartile range (IQR, 25%/75%) of spinal meningeal diverticula was 400 mm3 (210, 740) in ADPKD compared to 250 mm3 (180, 440) in controls (p<0.001). Mean/SD spinal meningeal diverticulum diameter was greater in the sacrum (7.3 + 4.1 mm) compared to thoracic (5.4 + 1.8 mm) and lumbar spine (5.8 + 2.0 mm), p<0.001, suggesting that that hydrostatic pressure contributed to enlargement. CONCLUSIONS: ADPKD has a high prevalence of spinal meningeal diverticula, particularly in women. ABBREVIATIONS: ADPKD = Autosomal dominant polycystic kidney disease.

20 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
CZChenglin Zhu
Chenglin Zhu
XHXinzi He
Xinzi He
JBJon Blumenfeld
Jon Blumenfeld
ZHZhongxiu Hu
Zhongxiu Hu
HDHreedi Dev
Hreedi Dev
Martin R PrinceMartin R Prince
Martin R Prince
Abdominal imaging of autosomal dominant polycystic kidney disease (ADPKD) has historically focused on detecting complications such as cyst rupture, cyst infection, obstructing renal calculi, and pyelonephritis; discriminating complex cysts from renal cell carcinoma; and identifying sources of abdominal pain. Many imaging features of ADPKD are incompletely evaluated or not deemed to be clinically significant, and because of this, treatment options are limited. However, total kidney volume (TKV) measurement has become important for assessing the risk of disease progression (i.e., Mayo Imaging Classification) and predicting tolvaptan treatment’s efficacy. Deep learning for segmenting the kidneys has improved these measurements’ speed, accuracy, and reproducibility. Deep learning models can also segment other organs and tissues, extracting additional biomarkers to characterize the extent to which extrarenal manifestations complicate ADPKD. In this concept paper, we demonstrate how deep learning may be applied to measure the TKV and how it can be extended to measure additional features of this disease.